CHRONIC MYELOID LEUKEMIA

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This study looks at whether people with chronic myeloid leukemia (CML) who have had a stable, deep response to treatment for at least two years can safely stop taking their daily targeted therapy (TKI). It involves 17 adults who have been on TKI for over three years. The main goa…

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a y…

This study tests a combination of two drugs, azacitidine and venetoclax, in people with a high-risk form of chronic myelomonocytic leukemia (CMML). The goal is to see if the combo can shrink or control the cancer better than current treatments. About 44 adults will take part, and…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia in patients who have already responded well to treatment. About 100 adults with chronic or accelerated phase CML will switch to a lower dose (20 mg every other day)…

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…

This study looks at whether taking nilotinib for two years can help people with chronic myeloid leukemia (CML) stay in remission after stopping their medication a second or third time. About 75 adults who previously tried and failed to stop treatment will take nilotinib and then …

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather pra…

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to un…